Article info

Original research
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Authors

  1. Correspondence to Professor Shukui Qin; qinsk{at}csco.org.cn
View Full Text

Citation

Mei K, Qin S, Chen Z, et al
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Publication history

  • Accepted February 14, 2021
  • First published March 19, 2021.
Online issue publication 
March 19, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.